Skip to main content

Table 3 Classification of disease severity

From: Evaluation of efficacy and safety of Qiangzhu-qinggan formula as an adjunctive therapy in adult patients with severe influenza: study protocol for a randomized parallel placebo-controlled double-blind multicenter trial

Classification

Features

1. Mild

Participants can continue to participate in the trial without medical treatment and impact on the health.

2. Moderate

Participants could not tolerate the drug or need medical treatment. Such events partially affect the participants’ functional activity without threat to life safety.

3. Severe

The events pose threat the life of participants, leading to death or disability, which requires immediate withdrawal of medicine or emergency monitoring treatment.